{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:33Z","timestamp":1783850193373,"version":"3.55.0"},"reference-count":29,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2018]]},"DOI":"10.7883\/yoken.jjid.2017.500","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T22:17:47Z","timestamp":1519769867000},"page":"122-128","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of In Vitro Expanded Virus-Specific T cells for Adoptive Immunotherapy against Virus Infection"],"prefix":"10.7883","volume":"71","author":[{"given":"Toshiaki","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo"},{"name":"Yokohama Municipal Citizen\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Matano","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases"},{"name":"Department of AIDS Vaccine Development, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Molecular Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kawana-Tachikawa","sequence":"additional","affiliation":[{"name":"AIDS Research Center, National Institute of Infectious Diseases"},{"name":"Department of AIDS Vaccine Development, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9-13.","DOI":"10.1016\/S0140-6736(95)91150-2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679-80.","DOI":"10.1056\/NEJM199409083311017"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925-35.","DOI":"10.1182\/blood-2009-08-239186"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV<sup>+<\/sup> lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119:2644-56.","DOI":"10.1182\/blood-2011-08-371971"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20:1622-32.","DOI":"10.1038\/mt.2012.130"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35: 3547-57.","DOI":"10.1200\/JCO.2017.73.0655"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6:242ra83.","DOI":"10.1126\/scitranslmed.3008825"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. O&apos;Reilly RJ, Prockop S, Hasan AN, et al. Virus-specific T-cell banks for &apos;off the shelf&apos; adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51:1163-72.","DOI":"10.1038\/bmt.2016.17"},{"key":"9","unstructured":"9. Vita R OJ, Greenbaum JA, Ponomarenko J, et al. The immune epitope database (IEDB) 3.0. Available at &lt;www.iedb.org&gt;. Accessed September 19, 2017."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Frahm N, Korber BT, Adams CM, et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol. 2004;78:2187-200.","DOI":"10.1128\/JVI.78.5.2187-2200.2004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003;77:2081-92.","DOI":"10.1128\/JVI.77.3.2081-2092.2003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kawana-Tachikawa A, Llibre JM, Bravo I, et al. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. PLoS One. 2014;9:e87334.","DOI":"10.1371\/journal.pone.0087334"},{"key":"13","unstructured":"13. DTU Bioinformatics. HLArestrictor--a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Available at &lt;http:\/\/www.cbs.dtu.dk\/services\/HLArestrictor&gt;. Accessed September 19, 2017."},{"key":"14","unstructured":"14. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Available at &lt;http:\/\/www.allelefrequencies.net\/&gt;. Accessed September 19, 2017."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.","DOI":"10.1056\/NEJM199510193331603"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 1993;11:213-44.","DOI":"10.1146\/annurev.iy.11.040193.001241"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Solache A, Morgan CL, Dodi AI, et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 1999;163:5512-8.","DOI":"10.4049\/jimmunol.163.10.5512"},{"key":"18","unstructured":"18. SYFPEITHI: database for MHC ligands and peptide motifs. Available at &lt;http:\/\/www.syfpeithi.de&gt;. Accsessed September 19, 2017."},{"key":"19","unstructured":"19. HLA peptide binding predictions. Available at &lt;https:\/\/www-bimas.cit.nih.gov\/molbio\/hla_bind\/&gt;. Accsessed September 19, 2017."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nastke MD, Herrgen L, Walter S, et al. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci. 2005;62:77-86.","DOI":"10.1007\/s00018-004-4363-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lidehall AK, Sund F, Lundberg T, et al. T cell control of primary and latent cytomegalovirus infections in healthy subjects. J Clin Immunol. 2005;25:473-81.","DOI":"10.1007\/s10875-005-5372-8"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother. 2008;31:199-206.","DOI":"10.1097\/CJI.0b013e31815ef862"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Vickers MA, Wilkie GM, Robinson N, et al. Establishment and operation of a good manufacturing practice-compliant allogeneic epstein-barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167:402-10.","DOI":"10.1111\/bjh.13051"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121:5113-23.","DOI":"10.1182\/blood-2013-02-486324"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Qasim W, Derniame S, Gilmour K, et al. Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154:150-3.","DOI":"10.1111\/j.1365-2141.2011.08579.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8<sup>+<\/sup> T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46-53.","DOI":"10.1038\/nm1520"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Abdel-Hakeem MS, B\u00e9dard N, Murphy D, et al. Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology. 2014;147:870-81. e8.","DOI":"10.1053\/j.gastro.2014.07.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Loh J, Popkin DL, Droit L, et al. Specific mutation of a gammaherpesvirus-expressed antigen in response to CD8 T cell selection in vivo. J Virol. 2012;86:2887-93.","DOI":"10.1128\/JVI.06101-11"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gottschalk S, Ng CY, Perez M, et al. An epstein-barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97:835-43.","DOI":"10.1182\/blood.V97.4.835"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/71\/2\/71_JJID.2017.500\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T09:48:50Z","timestamp":1693561730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/71\/2\/71_JJID.2017.500\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2017.500","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}